|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:brand
|
gptkb:Humulin_N
|
|
gptkbp:clinical_trial
|
blood sugar control
NC T00000123
NC T00000456
NC T00000789
|
|
gptkbp:contraindication
|
severe hypoglycemia
hypersensitivity to insulin
|
|
gptkbp:dosage_form
|
gptkb:tablet
vial
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:education
|
proper injection technique
recognize hypoglycemia symptoms
diet and exercise importance
monitor blood glucose
|
|
gptkbp:effective_date
|
gptkb:1982
|
|
gptkbp:formulation
|
suspension
intermediate-acting insulin
|
|
gptkbp:frequency
|
once daily
twice daily
|
|
gptkbp:highest_point
|
4 to 12 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Humulin N
|
|
gptkbp:ingredients
|
insulin isophane
|
|
gptkbp:interacts_with
|
gptkb:beer
beta-blockers
thiazide diuretics
|
|
gptkbp:is_used_for
|
gptkb:Company
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
pre-filled pen
multi-dose vial
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
insulin action
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:products
|
gptkb:Lantus
gptkb:Humulin_R
gptkb:Levemir
|
|
gptkbp:regulatory_compliance
|
prescription only
|
|
gptkbp:side_effect
|
weight gain
injection site reactions
hypoglycemia
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type
|
gptkb:drug
|
|
gptkbp:bfsParent
|
gptkb:Humulin
|
|
gptkbp:bfsLayer
|
4
|